Business Directory, Press Releases, Jobs, Products, Services, Articles
Businesses Articles Press Releases Follow @PRcom
Press Release Pricing | News by Category | News by Country | News by US Region | Recent News | News on Your Site

Press Releases


Press Release

Receive press releases from Gilad&Gilad: By Email PDF Version RSS Feeds:

Gilad&Gilad LLC Defends Agmatine Use Against Patent Infringements

Gilad&Gilad LLC issued a Cease and Desist Letter against a company for alleged infringements upon agmatine use patents.

Reseda, CA, September 08, 2015 --( Gilad&Gilad LLC has served a Cease and Desist Letter to a dietary supplement marketer for alleged patent infringements upon Gilad&Gilad's agmatine patents covering methods of use.

"As the discoverers of the neuroprotective properties of agmatine and the pioneers in introducing agmatine-containing products for nerve health into commerce, we are very pleased to see the continuously expanding use of our products for better quality of life," notes Dr. Gad M. Gilad, Gilad&Gilad's CEO. "There is an unmet need for a safe and effective supplement by millions who are coping everyday with great challenges to their nervous system health and with threats to maintaining resilient nerve functions."

Because of their discoveries, Gilad&Gilad's scientists were granted patents nos. 5,677,349 and 8,916,612 B2 for the use of agmatine to support healthy nerve functions and for its use at high dosages in dietary supplements, nutraceuticals and foods. The issue of these patents has been publicly announced in recent press releases by Gilad&Gilad and is indicated on Gilad&Gilad's website,

"As a business entity, the patents grant us a unique market position and provide protection to our discoveries and investments against infringements," Gilad adds. "However, it has recently come to our attention that, allegedly, a company is marketing and selling an agmatine-containing product with supplement facts and associated promoting materials on its website, in a white paper, in press releases and at commercial exhibits, which explicitly infringe on Gilad&Gilad's patents."

"We have invested enormous amount of resources and efforts in product development including scientific, clinical, safety and toxicity studies, as well as in ongoing clinical trials," Gilad emphasizes. "Thus far, we have not licensed our intellectual property to anyone. Gilad&Gilad will continue to watch for infringements and will undertake whatever legal action necessary to protect our property."

"As for now, there are no additional indications for agmatine usage which are backed by clinical studies," Dr. Gilad points out. "That agmatine is touted for bodybuilding, is completely unsubstantiated and is backed by outright false claims. The scores of companies now selling agmatine-containing products for bodybuilding are frankly deceiving and callous. These companies dupe customers and directly damage the reputation of the dietary supplement industry."

Gilad&Gilad has developed the exclusive For-Nerve-Health(TM) product line and markets the first-of-kind products, AgmaSet® and AgmaVet(TM), which contain G-Agmatine® (Gilad&Gilad's proprietary brand of agmatine).

*These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.

About Gilad&Gilad
Gilad&Gilad LLC is a privately owned, health science company with unique competency in Neuroscience. The principal mission of the company is to provide evidence-based safe and effective products of superior quality for healthier nervous system functions. The Company was founded by Dr. Gad M. Gilad and Ms. Varda H. Gilad following years of collaborative scientific research and based on their breakthrough discovery of the neuroprotective properties of G-Agmatine®, Gilad&Gilad's proprietary brand of agmatine. The Company has developed the exclusive For-Nerve-Health(TM) product line and markets the first-of-kind products, AgmaSet® and AgmaVet(TM). The Company builds its reputation by continuous investment in high standard scientific research and clinical studies, thus earning the trust of healthcare professionals and gaining credibility with the public. For further information about Gilad&Gilad please visit
Contact Information
Gad M. Gilad, PhD

Click here to view the list of recent Press Releases from Gilad&Gilad
Promote Your Business